A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
brief summary
The main aim of this study is to assess whether secukinumab treatment retention over 12 months in adult patients with moderate-to-severe plaque PsO receiving secukinumab in combination with a GLP-1 RA is non-inferior to that in patients receiving secukinumab monotherapy. The study will also evaluate adherence, long-term treatment retention, and healthcare resource utilization.
detailed description
This is a retrospective, non-interventional cohort study based on the secondary use of de-identified administrative claims data. The study will be conducted using two independent United States (US) real-world data sources.
The overall study period will span 21 January 2014 to 30 April 2026, and the cohort identification period will span 21 January 2015 to 30 April 2025. Adult patients with moderate-to-severe plaque PsO initiating secukinumab will be assigned to either a concurrent-therapy cohort (secukinumab + GLP-1 RA) or a secukinumab monotherapy cohort based on GLP-1 RA exposure around the secukinumab index date. Patients will be followed from secukinumab initiation (index date) until secukinumab discontinuation, end of continuous enrollment, end of the study period, death or applicable cohort-specific censoring events.
official title
Treatment Retention and Adherence to Secukinumab in Patients With Moderate-to-Severe Plaque Psoriasis With or Without GLP-1 Receptor Agonist Co-therapy: A Real-world Data Analysis